Allied Market Research


Hormone Refractory Prostate Cancer (hrpca) Market

Hormone Refractory Prostate Cancer (HRPCA) Market Size, Share, Competitive Landscape and Trend Analysis Report, by Therapy Type : Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals

Select an option
Author's: | Roshan Deshmukh
Publish Date:

Get Sample to Email

Hormone Refractory Prostate Cancer (HRPCA) or Castrate-Resistant Prostate Cancer (CRPC), a type of prostate cancer that typically recurs after having hormonal therapy, is now under the spotlight in prostate cancer market. Due to the high unmet clinical need associated with limited survival periods, intensifying HRPCA prevalence and fast-emerging treatment modifications, the global HRPCA market is poised to witness an unprecedented growth.

A promising drug pipeline, evolving treatment patterns and augmented patient awareness are the factors that would largely drive the market growth. Further, untapped patient population in the Asia Pacific region would lead to a large uptake of these treatments. On the other hand, premium pricing of HRPCA drugs, uncertain reimbursement policies and limited survival periods are likely to curtail the market growth.

Notably, physicians reluctance towards adoption of these premium treatments would remain a key challenge for the leading innovators. However, the untapped non-metastatic CRPC market would open new avenues for the new and existing companies. Additionally, emerging economies with undiagnosed patient population and mounting prevalence would provide growth opportunities in future.

The market is expected to register substantial growth attributed to the strategies adopted by leading market players. One of the key strategies adopted is collaboration agreement. For instance, in 2009, Astellas Pharma Inc. entered into an agreement with Medivation, Inc. to co-develop and co-commercialize MDV3100 (now Xtandi) for the treatment of HRPCA.

To provide a detailed market assessment, the report segments the HRPCA market on the basis of therapy type and geography. Based on therapy type, the market is segmented across various levels such as Chemotherapy, Hormonal Therapy, Immunotherapy and Radiation Therapy. The report covers a geographic breakdown and a detailed analysis of each of the aforesaid segments across North America, Europe, Asia Pacific, and LAMEA.

A comprehensive competitive analysis and the profiles of major market players such as Astellas Inc., Sanofi S.A, Dendreon Corporation, Bayer AG, Johnson & Johnson, and others are also provided in the report.


  • This report provides an extensive analysis of the current and emerging market trends and dynamics in the global HRPCA market
  • The HRPCA market scenario is comprehensively analysed in accordance with the key regions and leading countries
  • Extensive research is done for the market by therapy type which instils a clear understanding regarding the currently used chemotherapy and hormonal therapy drugs and evolving role of immunotherapies and radiopharmaceuticals
  • The report covers the detailed quantitative analysis of the current market and estimations¬†which would enable the stakeholders to capitalize on prevailing market opportunities
  • The studies evaluating competitive landscape and value chain has been taken into account in this report to help in understanding the competitive environment across the geographies
  • A detailed SWOT analysis enables to study the internal environment of the leading companies for strategy formulation
  • Owing to an emerging pipeline in the HRPCA market, clinical studies have also been taken into account to better understand the market potential and opportunities
  • Competitive intelligence highlights the business practises followed by leading market players across geographies

Hormone Refractory Prostate Cancer (HRPCA) Market Report Highlights

Aspects Details
By Therapy Type
  • Chemotherapy
    • Cytotoxic Agents
  • Hormonal Therapy
    • Anti Androgens
  • Immunotherapy
  • Radiation Therapy
    • Radio Pharmaceuticals
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players

Dendreon Corporation, AstraZeneca Plc, AbbVie Inc, Johnson and Johnson, Boston Biomedical Inc, AcceleronPharma Inc, Astellas Inc., Sanofi S.A, AB Science SA, Bayer AG

Loading Table Of Content...

Individual sections of the reports are available for purchase.
Would you like to see a breakdown of prices by section?

Hormone Refractory Prostate Cancer (HRPCA) Market

Global Opportunity Analysis and Industry Forecast, 2023-2032